The pathogenesis of Alzheimer's disease (AD) is a critical unsolved question; and although recent studies have demonstrated a strong association between altered brain immune responses and disease progression, the mechanistic cause of neuronal dysfunction and death is unknown. We have previously described the unique CVN-AD mouse model of AD, in which immune-mediated nitric oxide is lowered to mimic human levels, resulting in a mouse model that demonstrates the cardinal features of AD, including amyloid deposition, hyperphosphorylated and aggregated tau, behavioral changes, and age-dependent hippocampal neuronal loss. Using this mouse model, we studied longitudinal changes in brain immunity in relation to neuronal loss and, contrary to the predominant view that AD pathology is driven by proinflammatory factors, we find that the pathology in CVN-AD mice is driven by local immune suppression. Areas of hippocampal neuronal death are associated with the presence of immunosuppressive CD11c ϩ microglia and extracellular arginase, resulting in arginine catabolism and reduced levels of total brain arginine. Pharmacologic disruption of the arginine utilization pathway by an inhibitor of arginase and ornithine decarboxylase protected the mice from AD-like pathology and significantly decreased CD11c expression. Our findings strongly implicate local immune-mediated amino acid catabolism as a novel and potentially critical mechanism mediating the age-dependent and regional loss of neurons in humans with AD.
Introduction
Alzheimer's disease (AD) is a disease of aging associated with the accumulation of ␤-amyloid (A␤) peptides within the brain parenchyma and cerebral blood vessels and hyperphosphorylated and aggregated tau within neurons. Although the mechanisms causing brain atrophy and neuronal loss are unknown, increasing evidence suggests that immunity plays a critical role in AD pathogenesis. Genome-wide association studies have linked immune genes to increased risk for AD (Kamboh et al., 2012) . Recently, an integrated analysis of AD-associated genes demonstrated that AD neuropathology has the strongest association with changes in immune and microglial gene networks (Zhang et al., 2013a) . Despite this, we have not yet identified the specific mechanisms by which immunity contributes to AD pathogenesis. Although some studies have demonstrated increased expression of classical proinflammatory mediators in human AD, the inflammatory milieu also includes immunosuppressive components (Colton et al., 2006) . This immunosuppressive bias is consistent with the brain's status as an immune privileged site (Carson et al., 2006; Mellor and Munn, 2008; Ransohoff and Cardona, 2010) , and the contribution of immunosuppression to neuronal cell loss and other AD pathology remains largely unexplored.
In mice, transgenic expression of mutated human A␤ precursor protein (APP) leads to substantial A␤ deposition and behavioral deficits but does not commonly lead to tau pathology or neuronal death. As a result, mouse models of AD have been called "incomplete" models of human AD (Irizarry et al., 1997; Radde et al., 2008a) . In contrast, we have previously reported that CVN-AD mice, which are mNos2-deficient and transgenic for the Swedish K670N/M671L vasculotropic Dutch/Iowa E693Q/D694N mutant (APPSwDI) APP, display the cardinal characteristics of AD progression, including A␤ plaques, phosphorylated tau protein, spatial memory impairments, and significant hippocampal neuronal death Wilcock et al., 2008) . The prevention of inducible nitric oxide synthase (iNOS) protein expression in this model recapitulates the biology of human myeloid cells, which produce relatively little iNOS and nitric oxide (NO) (Weinberg et al., 1995; Geller and Billiar, 1998; Colton et al., 2008; Wink et al., 2011; Guo et al., 2012) . and commercially available as ABS535; Millipore). Secondary antibodies, ABC kit, and DAB kit were purchased from Vector Laboratories.
Quantitative RT-PCR. Frozen cryo-pulverized brain samples from CVN-AD, mNos2 Ϫ/Ϫ , WT, and APPSwDI mice at 6, 12, 24, 36, and 52 weeks of age were used to prepare RNA for analysis of immune gene expression. mRNA was extracted from frozen tissue using the RNeasy Tissue Kit (QIAGEN) according to the manufacturer's instructions. RNA was quantified using a NanoDrop spectrophotometer, and cDNA was generated using the cDNA high-capacity kit (Applied Biosystems). Real-time PCR was performed using the TaqMan Gene Expression kit (Applied Biosystems), according to the manufacturer's instructions and as previously described (Wilcock et al., 2011b) . All PCR probe sets were purchased from Applied Biosystems. Beta-actin served as the internal standard, and fold change in gene expression levels was calculated using the 2(Ϫdelta delta C(T)) method (Livak and Schmittgen, 2001) . WT mice at the same age were used as the comparator except where delineated.
Flow cytometry. Anesthetized mice were intracardially perfused with PBS, and brains were then rapidly harvested, manually dissociated, and digested for 1 h at 37°C with 1.5 mg/ml collagenase A (Roche Applied Science) and 0.4 mg/ml DNase I (Roche Applied Science) in 5% FBS with 10 mM HEPES. Cells from the digested tissue were then strained through a 70 m filter and washed with PBS. Cells were centrifuged in a 30% over 70% Percoll (Invitrogen) in PBS density gradient. Cells from the interface were isolated, and red blood cells were lysed with ammonium/chloride/potassium lysis buffer (Invitrogen). Cells were counted and then stained with Live/Dead Aqua (Invitrogen), and the following antibodies (all from eBioscience) were used: CD11b FITC, CD11c PE-Cy5.5, CD45 PE-Cy7, CD3 APC, Ly6G AF700, CD11b APC-Cy7, Ly6C V450, and IA-IE Qdot655. Flow cytometry was run on a BD LSR-II Flow Cytometer (BD Biosciences) in the Duke Human Vaccine Institute Flow Research Facility and analyzed with FlowJo (TreeStar).
Cell isolation by FACS and RNA isolation and amplification. CVN-AD, mNos2
Ϫ/Ϫ , and WT (C57BL/6 ) mice (n ϭ 4 per genotype), all at 48 weeks of age, were anesthetized and intracardially perfused with PBS. Cells were isolated for flow cytometry as described above. Cells were counted and stained with the following antibodies (all from eBioscience): CD11c PECy5.5, CD45 PE-Cy7, CD11b APC-Cy7, and Ly6G V450. FACS sorting was run on a BD FACS Aria II Special Order Research Product Flow Cytometer (BD Biosciences) in the Duke Human Vaccine Institute Flow Research Facility. Cells were gated on Ly6G Ϫ CD11b ϩ CD45 low microglia for mNos2 Ϫ/Ϫ , C57BL/6, and CVN-AD samples and further subgated into CD11c high and CD11c low populations in CVN-AD samples. A total of 1000 microglia were collected from each mNos2 Ϫ/Ϫ and C57BL/6 brain, and 1000 CD11c high and CD11c low microglia were collected per CVN-AD brain and sorted in a volume of 1.0 l directly into 6.4 l of SuperAmp Lysis Buffer (Miltenyi Biotec). Samples were then incubated at 45°C for 10 min and frozen at Ϫ20°C before shipment to Miltenyi Biotec on dry ice.
Microarray analysis. SuperAmp RNA amplification was performed by Miltenyi Biotec based on a global PCR protocol using mRNA-derived cDNA. cDNA integrity was checked via Agilent 2100 Bioanalyzer platform (Agilent Technologies). cDNA was labeled with Cy3 and hybridized to an Agilent Whole Mouse Genome Oligo Microarray 8ϫ60K. After washing and staining, fluorescence signals were detected with Agilent's Microarray Scanner System (Agilent Technologies). The Agilent Feature Extraction Software was used to read out and process microarray image files (Agilent Technologies). Partek Genomics Suite (Partek) was used for data analysis, where we ran an ANOVA with the four experimental groups to identify significantly differentially expressed genes. Significance threshold for the effect size was set at twofold change and false discovery rate at 5% (q ϭ 0.05).
Measurement of brain amino acids. Amino acids were extracted from cryo-pulverized 20-to 24-week-old mouse brain tissue (n ϭ 3-12 mice/ strain) using 4% CHAPS/50 mM EDTA solution with probe sonication. Stable-isotope-labeled internal standards for L-arginine, L-ornithine, and L-citrulline (Cambridge Isotope) were added to the extraction mixture following sonication and used for MS-based quantitation. Samples were clarified with centrifugation, subjected to solid phase extraction purifi-cation on Strata-X-C columns (Phenomenex), dried under air, and resuspended in isopropanol/0.2% formic acid. Analytes and their internal standards were then quantified in positive-ion liquid chromatographytandem mass spectrometry (LC-MS/MS) mode, using previously described methodology (Brown et al., 2011) . Briefly, separations were performed on an Atlantic hydrophilic-interaction chromatography (HILIC) column (Waters) with mobile phases of 75% acetonitrile/25% methanol/0.2% formic acid (mobile phase A) or 0.2% formic acid in water (mobile phase B) at 0.2 ml/min flow rate. Samples were introduced to a 4000 QTrap LC-MS/MS (AB SCIEX) via electrospray ionization, and analytes and internal standards quantified using multiple-reaction monitoring. Analyte concentrations were calculated from the slope of a calibration curve generated by serial dilutions of internal standards.
Difluoromethylornithine (DFMO) treatment. CVN-AD mice at 6 -8 weeks of age were treated with 10 mg/kg DFMO plus 1 mg/kg putrescine in saline by oral gavage 3 times a week (Mon/Wed/Fri) for 14 weeks (n ϭ 8 mice/ group). Control CVN-AD mice were treated on the same schedule using oral gavage with 1 mg/kg putrescine in saline alone (n ϭ 7 mice/group). DFMO (trade name Eflornithine; pharmaceutical grade) was provided by Dr. Patrick M. Woster, Department of Pharmacology, Wayne State University (Detroit) and was stored at Ϫ80°C and aliquoted at the time of use. Cotreatment with putrescine was used to reduce potential DFMO-mediated damage to the epithelial cells in the gastrointestinal tract. All mice were weighed twice per week, and no significant differences in weight were observed between DFMO-treated and salinetreated mice. After 14 weeks of treatment, mice were tested in the radialarm water maze (RAWM) for learning and memory. On completion of behavioral testing, brains were harvested for pathological assessment and gene analysis.
Two day Radial arm water maze (RAWM) test for learning and memory. CVN-AD, WT (C57BL/6 ), and mNos2
Ϫ/Ϫ mice were tested at the ages indicated using the 2 day RAWM described in detail previously (Alamed et al., 2006) . Briefly, a six arm maze is submerged in a black plastic pool of water, and a platform is placed at the end of one arm below the surface. The mouse receives 15 trials per day for 2 d (30 total) and is started in a different arm each trial while the goal arm containing the platform remains constant for each mouse. Using static visual cues, the mouse learns the position of the escape platform. On the first day, the first 12 trials are considered training and alternate between a visible and a hidden platform, whereas the final 3 trials use a hidden platform. All trials on day 2 use a hidden platform. The number of errors (incorrect arm entries) is counted over a 1 min period. The errors for each consecutive three trials (1-3, 4 -6, 7-9, 10 -12, 13-15) are averaged as one block, resulting in 5 blocks per day. After completion of all hidden maze tasks, mice were tested for sensory or motor deficits using the open pool task with visible platform as described previously (Alamed et al., 2006) . Mice that did not perform successfully in the open pool task were excluded from data analysis. All behavioral tests were performed with treatment groups blinded to the investigator.
Statistical analysis and comparisons between groups. Average values Ϯ SEM were determined for each of the outcome measures at 6, 12, 24, 36, and/or 52 weeks of age in the CVN-AD and control mice. Mixed genders were used in the analyses, and gender based-differences were not investigated. Significant differences across age within strain were determined using one-way ANOVA, and statistical significance between genotypes and age was determined by two-way ANOVA using the PRISM statistical program (GraphPad Software). Significance was set at p Յ 0.05. The number of mice analyzed ranged from 3 to 14 mice per group depending on the outcome assay.
Results
Immune suppression is an early feature of disease progression CVN-AD mice display characteristic neuropathology resembling human AD as they age, which include the accumulation of A␤ deposits starting at 6 weeks of age, the presence of hyperphosphorylated and aggregated tau beginning at 12 weeks of age, spatial memory deficits beginning ϳ24 weeks of age, and neuronal loss at ϳ36 weeks of age . We thus reasoned that these mice could be used to identify immune abnormalities that arise early in the course of disease as well as with disease progression during aging. We used qRT-PCR of total brain lysate to measure gene expression for a variety of proinflammatory and anti-inflammatory genes implicated in AD in CVN-AD, mNos2 Ϫ/Ϫ , and WT (C57BL/6 ) mice at 6, 12, 24, 36, and 52 weeks of age. We also examined mRNA expression levels in the parent APPSwDI strain to determine whether A␤ accumulation alone was a factor in the immune changes, as levels of soluble and insoluble A␤ are not significantly different in APPSwDI versus CVN-AD mice (Wilcock et al., 2008) . Because significant neuronal death begins ϳ36 weeks in CVN-AD mice , we grouped the genes into two major patterns of expression: genes that were upregulated before 36 weeks (Fig. 1A-D) and genes upregulated at or after 36 weeks (Fig. 1E-I ). We also examined gene expression levels for chemokine receptors and ligands from 6 to 52 weeks of age (Fig. 1J-L) .
Genes that were upregulated at the earliest time points in CVN-AD mice were predominately those that have been linked to immune suppression in macrophages (Fig. 1) . This included arginase-1 (Arg1), Found in Inflammatory Zone 1 (Fizz1), and interleukin 1 receptor antagonist (Il1rn). These genes tended to display the highest expression level only transiently, returning toward WT control levels by 24 weeks. Expression of these antiinflammatory genes was significantly greater in CVN-AD mice compared with the parent APPSwDI strain, with the exception of Arg1 expression at 12 weeks of age, where a small increase in mRNA level was observed in APPSwDI brain lysates. Interleukin-1␤ (Il1b), the classic proinflammatory mediator, was also expressed early in CVN-AD mice, beginning at 12 weeks of age. After this initial peak, IL-1␤ gene expression levels remained significantly elevated throughout the 52 weeks of the study. Compared with APPSwDI mice, which exhibited only slight increases in Il1b and Il1rn at 24 and 52 weeks, CVN-AD mice had greater expression levels for Il1b and Il1rn at all time points.
Specific genes that were increased in CVN-AD mice at or after 36 weeks of age included the canonical proinflammatory gene Tnfa, which was significantly increased only at the latest time point studied (52 weeks), and Tgfb, an anti-inflammatory gene that was increased transiently beginning at 36 weeks of age. Also increased was Cd33 (Siglec-3), an inhibitory lectin that has been implicated in genome-wide association studies of AD and that is believed to alter microglial phagocytosis of A␤ (Salminen et al., 2009; Bradshaw et al., 2013) . Other immunosuppressive genes known to be associated with AD, namely, Trem2 and Tryobp (DAP12), were also increased late in disease progression in CVN-AD mice. Data from APPSwDI mice brain showed a similar age-specific pattern of expression for these late genes, but no significant changes were found in either mNos2 Ϫ/Ϫ or wild-type control mice at any age.
Expression of mRNAs for the chemokine receptor Ccr2 (Fig.  1J ) and its ligand Ccl2 (MCP1) (data not shown) was unchanged at all time points in CVN-AD brains. Ccr2 is expressed on inflammatory monocytes and has been shown to mediate the migration of these cells from the periphery into the brain in mice expressing mutated human APP (El Khoury et al., 2007; Naert and Rivest, 2011) , although others have observed that circulating monocytes from humans with AD have depressed CCR2 expression (Zhang et al., 2013b) . Expression of Cxcl1 (KC, GROa), which can mediate neutrophil recruitment and may have a role in neuroprotection, and Ccl11 (eotaxin 1), a chemoattractive factor for eosinophils, also remained unchanged (data not shown). How-ever, Ccr1 and Cx3cr1 expression was significantly increased in CVN-AD mice but was not observed in any of the control mice, including APPSwDI mice. Increased Ccr1 expression in CVN-AD mice was observed early and elevated at all ages. CCR1 has been shown to associate with plaques in the entorhinal cortex and hippocampus, is an early marker for clinical dementia in humans with AD, and has been shown to directly correlate with cognitive decline (Halks-Miller et al., 2003) . Expression of Cx3cr1, which is expressed primarily by microglia in the brain, increased progressively in CVN-AD brains (Fig. 1L) , consistent with the increasing number of microglia (see Fig. 3 ). However, gene expression for Cx3cr1 receptor ligand, Cx3cl1 (fractalkine), was not increased at any time (data not shown).
CVN-AD mice show progressive cellular inflammation with CD11c
؉ microglia in areas of A␤ deposition To better understand the cellular basis of the altered immune responses found in whole-brain lysates of CVN-AD mice compared with control mice, we examined the presence and characteristics of typical immune cells using immunocytochemistry on brain sections through one year of the disease process. Agematched mNos2 Ϫ/Ϫ and C57BL/6 mice were used as controls. Immune markers that are characteristically upregulated in tissue sections from autopsied human AD brain include CD45, MHC-II, CD11b, and CD11c (Rozemuller et al., 1986; McGeer et al., 1987; Rogers et al., 2002; Mrak and Griffin, 2005; Eikelenboom et al., 2010) . Changes in these markers are used as a pathological indicator of the immune response in humans with AD and are also observed in mouse models of AD (Tan et al., 2000; Butovsky et al., 2006; Nichol et al., 2008; Tambuyzer et al., 2009; Mildner et al., 2011) . In CVN-AD mice, tissue expression of CD45, Iba-1, and CD11c is correlated with amyloid deposition with aging ( Fig.  2) . A␤ plaques appeared initially in the subiculum of the hippocampus and increased in staining density throughout the cortex and hippocampus with age ( Fig. 2A-D) . A␤ deposition was accompanied in time and spatial location by increased immunoreactivity for CD45 ( Fig. 2E-H ). CD45 ϩ cells had the morphological features of reactive microglia with bushy, shortened processes (data not shown). To confirm that CD45 cells in CVN-AD brains represent microglia, sections from the same Figure 1 . Expression of immune-related genes from whole-brain lysates. Average values and SEM for the relative change in mRNA levels are shown for immune-related genes from whole-brain lysate samples from CVN-AD, mNos2 Ϫ/Ϫ , WT (C57BL/6 ), and APPSwDI mice. A-D, Genes that were upregulated in CVN-AD mice before 36 weeks of age. E-I, Genes that were upregulated in CVN-AD mice at or after 36 weeks of age. J-L, Gene expression of chemokine receptors. mRNA expression was measured using quantitative RT-PCR and represent the 2(Ϫdelta delta C(T)) compared with WT mice. Samples were analyzed by two-way ANOVA and post hoc multiple comparison test with Bonferonni's correction. *Comparisons between CVN-AD or APPSwDI and WT.
# Comparisons between CVN-AD and APPSwDI mice. *p Ͻ 0.05. **p Ͻ 0.01. ***p Ͻ 0.001. ****p Ͻ 0.0001.
CVN-AD mice were stained with Iba-1, a calcium binding protein that is expressed specifically on microglia in the CNS (Fig.  2I-L) . Iba-1 stained microglia throughout the brain, as well as cells within the hippocampus and cortex that correlated with the pattern of CD45 staining in these mice. We also examined the expression pattern of CD11c, which is not commonly found on either resting or reactive microglia in mouse brain, but is found on resting and activated human microglia ). An increasing pattern of expression was similar to that of CD45 was observed for CD11c ( Fig. 2M-P) , and CD11c expression found to overlap with Iba-1 ϩ microglia using double labeling techniques (Fig. 2Q) . To further confirm the change in levels of CD11c with age, we also performed qRT-PCR on whole-brain lysates. Gene expression levels for Itgax (CD11c) increased dramatically from 6 weeks of age, leading to an ϳ100-fold increase at 52 weeks of age (Fig. 2R) . In contrast, the expression levels of Itgax mRNA in the APPSwDI parent mouse strain showed a relatively delayed increase in gene expression levels and were significantly less than the fold changes in mRNA found in CVN-AD mice brain. Similarly, we observed less and delayed CD11c immunostaining at all ages when comparing APPSwDI with CVN-AD mice (data not shown). No changes in CD11c mRNA levels were found for mNos2 Ϫ/Ϫ or WT mice brain lysates at any age studied.
The above findings suggest that cellular inflammation in CVN-AD mice is primarily due to an increased number of reactive microglial cells that coexpress CD45 and CD11c. To confirm the identity of the CD11c ϩ cells, we performed 12-color flow cytometric analysis of homogenized whole brains from 42-weekold mNos2 Ϫ/Ϫ , which lack CD11c ϩ microglia, and CVN-AD 
mice (Fig. 3) . Using this technique, we found increased total cell numbers in the brains of CVN-AD mice that was caused by a significant increase in the numbers of CD45 low CD11b ؉ microglia, and secondarily, by a trend toward increased numbers of T cells (Fig. 3B) . The total numbers of B cells, neutrophils, eosinophils, macrophages, Ly6C low resident monocytes, and Ly6C high inflammatory monocytes, however, were unchanged in CVN-AD brains (Fig. 3B) . CD11c was predominantly expressed by CD45 low microglia (Fig. 3C ). At 42 weeks of age, ϳ12.2 Ϯ 2.5% of all microglia were CD11c ϩ , compared with 2.24 Ϯ 0.3% in mNos2 Ϫ/Ϫ controls, and there was a significant increase in the mean fluorescence intensity of microglial expression of CD11c (Fig. 3D) . Thus, both immunocytochemical and flow cytometric analyses demonstrated that CVN-AD mice develop substantial cellular inflammation that is caused primarily by the expansion of microglial cells. These microglial cells display a reactive morphology, accumulate specifically in areas of A␤ deposition, and can be distinguished from microglia in control mice by their increased expression of CD11c. This pattern of cellular inflammation is consistent with that seen in humans with AD (Dickson et al., 1988; Akiyama and McGeer, 1990 ).
CD11c
؉ microglia show an immunosuppressive phenotype To better understand the potential functional capabilities of the CD11c-immunopositive microglia in CVN-AD mice, we used flow sorting to isolate this population from whole-brain lysates. Mice were used at 48 weeks of age to ensure a large population of cells for the study. Cells were gated on Ly6G Ϫ CD11b ϩ CD45 low microglia for mNos2 Ϫ/Ϫ , WT, and CVN-AD brain samples and further subgated into CD11c high and CD11c low populations in CVN-AD mice. Messenger RNA from each collected cell sample was then globally amplified using SuperAmp to produce cDNA for use in an Agilent Whole Mouse Genome Oligo microarray. Gene expression from the CVN-AD CD11c ϩ cells was compared with that of the Ly6G Ϫ CD11b ϩ CD45 low CD11c Ϫ microglia from CVN-AD, C57BL/6, and mNos2 Ϫ/Ϫ brains. ANOVA with the four experimental groups was used to identify significantly differentially expressed genes. We set the significance threshold for the effect size at twofold change and false discovery rate at 5% (q ϭ 0.05).
Approximately 375 genes were significantly upregulated and 85 genes downregulated in CVN-AD CD11c ϩ microglia compared with CD11c
Ϫ microglia from CVN-AD, C57BL/6, and mNos2 Ϫ/Ϫ brains (Table 1 ). Upregulated genes included those genes that are used to identify microglia in humans with AD, such as Itgax (Cd11c/LeuM5; CR4) and Cd200r (Cell surface glycoprotein CD200 receptor 2; OX2R). The 124-fold increase in Itgax gene expression verified our previous observations and our FACS isolation process. Strikingly, many of the genes that were upregulated in CVN-AD CD11c ϩ microglia, such as Spp1, Wfdc17, Gp49a, Apoe, and Pdcd1, were genes associated with immune suppression and increased arginase activity. Similarly, many of the genes that were downregulated were from proinflammatory pathways, such as Apobec3, Ifngr1, and Siglech, or represent negative regulators of immune suppression, such as Klf6 (Table 1) . Together, along with additional genes that were changed significantly ( microglia from CVN-AD mice had a predominantly immunosuppressive phenotype.
CVN-AD pathology is associated with increased arginine utilization and decreased brain arginine bioavailability
The immunosuppressive phenotype observed in CVN-AD mice brain suggested a potential causative role for this immune process in disease progression. In particular, Arg1, a critical antiinflammatory gene that codes for the enzyme arginase-1, was expressed predominantly in young mice in brain areas associated with A␤ deposits but before neuronal loss in this model of AD. and Mizushima, 2010) . To determine whether induction of Arg1 may play a role in AD-like pathology in CVN-AD mice, we examined arginase-1 protein expression and its spatial and temporal relationship with A␤ deposition and CD11c ϩ microglial at different ages using immunocytochemistry. Arginase-1 protein accumulated in the subiculum and CA1 regions of the hippocampus, areas of primary neuronal loss, starting between 6 and 12 weeks and peaked at 24 weeks (Fig. 4A) , consistent with the onset of behavioral deficits at 24 weeks. In contrast, no arginase-1 staining was observed at any time point in Nos2 Ϫ/Ϫ brains ( Fig. 4B ; and data not shown). Of note, arginase-1 staining in CVN-AD brains did not primarily localize to cells but instead diffusely stained the hippocampus and subiculum, suggesting that arginase was distributed in the extracellular space surrounding the cells (Fig. 4B) . Additionally, arginase-1 staining in the hippocampus displayed a spatial correlation with that of A␤, Iba-1, and CD11c (Fig. 4C) , highly suggesting that CD11c ϩ microglia are a likely source of arginase-1 production and that expression is associated with A␤.
To determine whether arginase-1 expression alters brain arginine levels in CVN-AD mice, we examined brain amino acid levels and the compensatory expression of amino acid transporters in these animals. Total brain arginine and arginine metabolites, including ornithine and citrulline, were measured using HILIC and LC-MS/MS (Brown et al., 2011) . In disease contexts, the global arginine bioavailability ratio (GABR), which is the ratio of arginine to its metabolites ornithine and citrulline (arginine/(ornithine ϩ citrulline)), is often a better indicator of dysregulated arginine metabolism than arginine concentration alone (Tang et al., 2009; . Calculating the GABR revealed that, compared with WT, mNos2 Ϫ/Ϫ , and APPSwDI mice, CVN-AD mice had significantly reduced GABR (Fig. 5A) , indicating that CVN-AD brains exhibited increased arginine catabolism.
Cells deprived of arginine attempt to compensate by increasing expression of amino acid transporters that regulate the cellular uptake of arginine from the local environment (Hyatt et al., 1997; Bröer, 2002; Closs et al., 2006) . To determine whether such mechanisms were active in CVN-AD brains, we measured wholebrain lysate mRNA levels of cell membrane-bound amino acid transporters that mediate arginine uptake (Fig. 5B-E) . These included cationic amino acid transporter 1 (CAT1; Slc7A1), cationic amino acid transporter 2 (CAT2; Slc7A2), cationic amino acid transporter 3 (CAT3; Scl7A3), and the large neutral amino acid transporters LAT1 (Slc7A5) and LAT2 (Slc7A8). We observed no significant changes for all of these genes in Nos2 Ϫ/Ϫ , C57BL/6, and APPSwDI mice (Fig. 5B-E) . In contrast, in CVN-AD brain, we found that LAT1 mRNA was consistently increased from 12 weeks through 52 weeks (Fig. 5B) . We also observed transient increased gene expression for LAT2, CAT1, and CAT2 at 12 weeks of age and returning to baseline expression levels by 24 weeks (Fig. 5C-E) . CAT3 showed no significant change at any age (data not shown), consistent with its restricted expression on a small number of neuronal populations (Hosokawa et al., 1999) . These changes in GABR and arginine transporters indicate that, compared with control strains, CVN-AD mice have dysregulated arginine metabolism.
Blockade of arginine utilization reverses memory loss
Our data on arginase expression and arginine depletion in the brains of CVN-AD mice raised the possibility that chronic brain arginine deprivation promotes neurodegeneration. To determine whether there is a causal relationship between arginine depletion and the development of pathology and cognitive defects in CVN-AD mice, we reduced the biological effects of arginine catabolism by blocking key enzymes in the arginine utilization Ϫ/Ϫ and CVN-AD stained for arginase-1. Scale bars: top, 500 m; bottom, 50 m. C, Sister coronal sections from the same 52-week-old CVN-AD brain stained for A␤, CD11c, Iba-1, and arginase-1 to show regional associations.
pathway (Fig. 6) . We chose to use eflornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) (Abeloff et al., 1984; Pepin et al., 1987; Seiler, 2003) and a partial inhibitor of arginase that has been previously used to block arginine utilization in vivo (Selamnia et al., 1998) . Because the polyamine pathway, which is downstream of ODC, is important for cell proliferation particularly in the gastrointestinal system (Buts et al., 1993), we supplemented CVN-AD mice with putrescine to reduce gastrointestinal damage created by decreased polyamine levels (Kameji et al., 1979; Löser et al., 1999) .
Two treatment groups were established: CVN-AD mice treated with oral gavage of putrescine alone and CVN-AD mice treated with oral gavage of putrescine plus DFMO. Because increased arginase-1 mRNA and protein levels were observed at the earliest time points in the disease process, treatment was started at 6 -8 weeks of age with oral gavage 3 times a week for 14 weeks. Immediately on conclusion of treatment, we tested learning and memory behavior in the putrescine only-treated and DFMO plus putrescine-treated mice. We have previously demonstrated that CVN-AD mice have deficits in spatial memory as measured by RAWM and make significantly more errors than either mNos2 Ϫ/Ϫ or C57BL/6 controls at 24 weeks of age . CVN-AD mice treated with DFMO plus putrescine demonstrated significantly improved acquisition and recall compared with vehicle (putrescine only)-treated CVN-AD mice (Fig. 6A) , suggesting that blockade of arginine catabolism reverses the behavioral phenotype of memory loss found in CVN-AD mice.
To determine whether this reversal was associated with previously identified AD-like pathologies, we measured levels of both soluble and insoluble A␤ 40 and A␤ 42 in whole-brain lysates. We found that soluble and insoluble A␤ 40 and A␤ 42 were significantly reduced by DFMO plus putrescine treatment (Fig. 6B) . To determine whether neuronal numbers were altered, the number of neurons in the CA3 region of the hippocampus was counted using unbiased stereology. As we expected, we found no difference in the number of hippocampal neurons between treatment groups of 20-to 24-week-old mice, as CVN-AD mice do not develop significant neuronal loss until ϳ36 weeks of age (data not shown). We measured mRNA levels for Itgax (CD11c) in wholebrain lysates from these mice and found that Itgax expression was significantly reduced in the DFMO-treated group (Fig. 6C) . We also measured Pdcd1, a principal immunosuppressive gene that regulates arginase activity and T-cell activity Krempski et al., 2011) and was highly increased in our gene screen. DFMO treatment significantly reduced Pdcd1 expression (Fig. 6C) . Genes associated with arginine utilization were also measured. As expected, Arg1 mRNA levels did not change, whereas gene expression for spermine synthase s-acetyltransferase, which is induced by polyamine activity (Colton et al., 2004; Krempski et al., 2011) , was significantly decreased by DFMO treatment (Fig. 6C) . Immunohistochemical staining for A␤ revealed that DFMO treatment in CVN-AD mice resulted in less A␤ plaques, particularly in the cortex and thalamus, and to a lesser extent, in the hippocampus. Similarly, we found that DFMO-treated CVN-AD mice had less CD11c ϩ cells in the cortex, thalamus, and hippocampus. Interestingly, treatment with DFMO was less efficacious for reducing A␤ and CD11c in the subiculum of the hippocampus (Fig. 6D) . Together, these observations indicate that treatment with DFMO reversed arginine utilization and prevented AD pathology.
Discussion
Our studies using CVN-AD mice show that: (1) CD11c ϩ microglia accumulate at sites of A␤ deposition, (2) these microglia show an immunosuppressive phenotype, (3) extracellular arginase accumulates in these same regions, (4) global arginine bioavailability significantly decreases, and (5) inhibition of abnormal arginine utilization results in a marked improvement in pathology and cognitive function. Importantly, CD11c ϩ mi- The role of immunity in AD pathogenesis is a critical and unresolved question. One current view proposes that extracellular A␤ peptide activates CNS immune cells, including microglia and perivascular macrophages, to produce inflammatory cytokines, such as TNF␣, IL-1␤, and reactive nitrogen or oxygen species that initiate neuronal death. Although this type of response is clearly observed in acute brain diseases, such as bacterial or viral infection and trauma, our data suggest that proinflammatory toxicity is not a primary factor in AD pathogenesis and associated neuronal cell loss. Although increased proinflammatory genes are observed in the CVN-AD mice with increasing age, these changes are late in the course of the disease and counteracted by increased expression of immunosuppressive genes (IL1Ra, TGF␤, CD33, TREM2, and DAP12) . We propose, instead, that a different type of immune pathology that involves immune suppression leads to neuronal death. In association with A␤ deposition, a subset of resident brain microglia assume a specific immunosuppressive phenotype that includes expression of Figure 6 . CVN-AD memory deficits and pathology are reversed by an inhibitor of arginine utilization. A, RAWM assessment of spatial memory acquisition and recall in CVN-AD mice treated with putrescine (put.) alone or putrescine and DFMO (10 mg/kg) by oral gavage for 3 d/week for 14 weeks. All mice were naive to the behavioral procedure and tested on the final 2 d of treatment. Day 1 depicts 5 trial groups for the acquisition phase (learning), and day 2 depicts successive trials for memory recall. Data represent the average number of errors (Ϯ SEM) made finding the escape platform for each group of trials. Open circles represent CVN-AD mice treated with putrescine and vehicle. Closed circles represent CVN-AD mice treated with DFMO and putrescine. Data were analyzed by two-way ANOVA and post hoc multiple comparison test with Bonferonni's correction. ***p Ͻ 0.001. n ϭ 7 or 8 mice per group. B, Soluble and insoluble A␤40 and A␤42 peptides in total brain homogenates from CVN-AD mice treated with vehicle containing putrescine only or putrescine plus DFMO as measured by ELISA. Data represent average levels (Ϯ SEM) of A␤40 or A␤42 peptides. ***p Ͻ 0.001 for DFMO-treated compared with putrescine/vehicle-treated using an unpaired Student's t test. n ϭ 7 or 8 mice/group. C, DFMO treatment alters mRNA levels of immune genes. Average mRNA expression levels (Ϯ SEM) for Itgax, Pdcd1 (programmed death receptor 1), Arg1, and Ssat were measured in total brain lysates from CVN-AD mice treated with putrescine in vehicle or putrescine and DFMO. Gene expression levels were measured using quantitative RT-PCR and represent the 2(Ϫdelta delta C(T)) with untreated mice as the comparator. Significance between untreated and treated was determined using the unpaired Student's t test. *p Ͻ 0.05. **p Ͻ 0.01. n ϭ 7 or 8 mice per group. D, Representative sagittal sections from CVN-AD mice treated with either putrescine alone or putrescine and DFMO stained for A␤ or CD11c. For each treatment group, panels represent sister sections from the same mouse. Scale bar, 500 m. CD11c and production of extracellular arginase, which acts to deplete brain extracellular arginine levels.
In contrast with other tissues, the brain is particularly susceptible to arginine deprivation as arginine is actively transported into the brain via rate-limiting amino acid transporters (Boado et al., 2004; Hawkins et al., 2005 Hawkins et al., , 2006 Closs et al., 2006) . Whereas baseline blood arginine levels are ϳ115 M, whole-brain arginine is ϳ50 M and even lower in the hippocampus (Dawson et al., 2004; Erdely et al., 2010) . Furthermore, under inflammatory conditions, endogenous arginine synthesis and transport at the blood-brain barrier are decreased. Thus, prolonged and abnormal immune-mediated activation of arginine utilization pathways in susceptible brain regions, such as the hippocampus, may further reduce already low arginine levels, facilitating neuronal damage. When arginine utilization is interrupted by treatment with the arginase and ODC inhibitor DFMO, we show that AD-like pathology is prevented. Further studies will be required to confirm that DFMO improves arginine bioavailability and to determine whether arginase blockade can protect against neuronal death and memory deficit in a therapeutic fashion.
Our findings strikingly reflect previous observations from human AD. CD11c ϩ microglia are a well-known feature of human AD pathology, although their functional role has not been explicitly defined Tooyama et al., 1990; Dick et al., 1997; Walker and Lue, 2005) . Direct evidence also supports that dysregulated arginine utilization may contribute to human AD. We and others have demonstrated that arginase mRNA expression and enzymatic activity are increased in human AD brain samples (Colton et al., 2006; Hansmannel et al., 2010; Liu et al., 2014) . Consistent with increased arginase activity, the frontal cortex of AD patients has significantly decreased levels of L-arginine and L-ornithine (Gueli and Taibi, 2013) . Furthermore, others have found increased polyamines (putresecine, spermidine, and spermine), the downstream products of arginase activity, in human AD brain (Inoue et al., 2013) . Amino acid starvation leads to GCN2 kinase-mediated phosphorylation of eIF2␣, leading to cell autophagy or apoptosis (Young et al., 2009; Altman and Rathmell, 2012) . Indeed, increased phosphorylation of GCN2 kinase has been observed in human AD brain , suggesting that the integrated stress response pathway is activated as a result of amino acid deprivation. Collectively, these data support that arginine utilization, which is immune regulated, can be dysfunctional in AD and impact neurodegeneration.
Arginine is the sole substrate of two opposing enzyme systems: the iNOS pathway and the arginase pathway (Fig. 7) . Both iNOS and arginase are immune regulated; and, in general, iNOS is associated with the proinflammatory phase of an immune response and arginase is associated with the anti-inflammatory phase. iNOS and arginase are often coexpressed, but competition between these two opposing enzymes favors arginase because of its higher expression level and greater V max (Morris, 2007; Wu et al., 2009) . In humans, in contrast to C57BL/6 mice, the competitive advantage is further skewed in favor of arginase. hNOS2 expression is tightly regulated through promoter differences and posttranscriptional repressors, resulting in less iNOS-mediated NO production in humans compared with mice Ganster et al., 2001; Mestas and Hughes, 2004; Guo et al., 2012) . iNOS transcript, protein, and protein activity are unchanged or even decreased in human AD (Colton et al., 2006; Liu et al., 2014) . Low iNOS enzymatic activity also increases arginase enzyme activity due to the loss of N-()-hydroxy-L-arginine, an intermediate in the L-arginine to NO metabolic pathway and inhibitor of arginase (Boucher et al., 1999; Tenu et al., 1999) .
Our findings offer one explanation for why most mouse models of AD show abundant A␤ deposition but, despite large increases in proinflammatory cytokines, do not show significant neuronal cell loss (Irizarry et al., 1997; Radde et al., 2008b) . By crossing mutant APPSwDI mice onto an mNos2-deficient background, we developed a mouse model of AD that more closely mimics the reduced iNOS activity found in humans . In contrast to CVN-AD mice, the parent APPSwDI mice had much reduced expression of arginase at all ages and showed no changes in arginine transporter mRNA or global arginine bioavailability. Furthermore, reconstituting the human NOS2 gene into the CVN-AD mouse strain resulted in equivalent AD-like pathology as found in CVN-AD mice , demonstrating that reducing NOS2 expression to more human-like levels favors arginase in the competition for arginine and highlights the species difference in NOS2 regulation of arginine utilization. Interestingly, this shift in immune-mediated redox conditions likely accounts for the accelerated and more prominent expression of CD11c, although the mechanisms governing this difference are unknown.
The exact cell type associated with increased arginine consumption remains unclear. Neurons, astrocytes, microglia, and circulating monocytes are all capable of expressing arginase-1; thus, each (or all) may participate in depletion of extracellular arginine. However, few neurons demonstrate arginase immunoreactivity, and the neuronal expression of arginase appears to be limited to specific tracts in the visual cortex and cerebellum . Astrocytes express a similar profile of arginine transporters to microglia and may actively reduce environmental arginine levels via robust uptake. Future studies are required to understand the kinetics and cellular origin of arginase expression, particularly in human AD pathology. However, we hypothesize that microglia are the primary source for arginine consumption. First, A␤ itself may initiate induction of immunosuppression in microglia (Kurnellas et al., 2013) . Second, similarly to our observations, human myeloid cells commonly release extracellular arginase under pathologic conditions, as has been observed in glioblastoma and other tumors (Raychaudhuri et al., 2011) . The appearance of CD11c ϩ microglia very early in pathology and their tight correlation with AD pathology and extracellular arginase support a role for this subtype of microglia in immunemediated arginase release. Importantly, when we blocked arginase utilization in CVN-AD mice, we found significantly decreased expression of CD11c.
Although it cannot be firmly established with the present data, we anticipate that the CD11c ϩ cells arise from the brain's endogenous microglial population and not from infiltrating monocytes. Influx of Ly6C ϩ inflammatory monocytes into the mouse brain depends largely on expression of CCR2 and its ligands (El Khoury et al., 2007; Mildner et al., 2007) , and no change was observed in total brain expression of CCR2 or CCL2 in CVN-AD mice at any age. Although infiltrating Ly6C ϩ monocytes could comprise a rare cell population, and thus total brain Ccr2 would be unchanged, we also did not observe any significant increase in brain monocytes at multiple ages by flow cytometry. Supporting these findings, Zhang et al. (2013b) previously demonstrated that monocytes from humans with AD have decreased expression of CCR2, suggesting decreased capacity for chemotaxis. In concordance with data from human AD, we found increased CCR1 expression in CVN-AD brain, although how CCR1 regulates chemotaxis in AD remains unknown (Halks-Miller et al., 2003) . Thus, although our data highly implicate endogenous hippocampal microglia and not peripheral cells, further studies are required to prove this point.
In conclusion, based on our analysis of CNS immunity during aging in a mouse model of AD, we conclude that, contrary to the predominant paradigm that AD pathology is driven by proinflammatory factors, our data support an alternative mechanism for neuronal death in AD. We suggest that immune suppression and arginine catabolism lead to a loss of arginine, a critical semiessential amino acid, and this nutrient deprivation is followed by cell death. This is a novel and potentially critical mechanism that may explain the temporal and spatial induction of the slow and persistent loss of neurons in humans with AD.
